• HUYA Bioscience International Presents Positive Data On HBI-8000 at Society for Immunotherapy of Cancer Meeting

    21 days ago - By San Diego Biotechnology

    Study confirms tolerability and significant anti-tumor activity of HBI-8000 in combination with nivolumab in checkpoint naive melanoma patients
    SAN DIEGO, Nov. 9, 2020 /PRNewswire/ - HUYA Bioscience International , the leader in accelerat......
    Read more ...